Yahoo Web Search

  1. Web results

  2. Xanodyne Pharmaceuticals, Inc. manufactures, markets and/or distributes 1 drug in the U.S.

  3. Xanodyne Pharmaceuticals, Inc. - MPM Capital

    Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management.

  4. Xanodyne Pharmaceuticals, Inc.: Private Company Information ...

    Xanodyne Pharmaceuticals, Inc. company research & investing information. Find executives and the latest company news.

  5. People come first at Ferring. at Ferring, we define ourselves with a single word. ... This site contains material about Ferring Pharmaceuticals Inc. ...


    Edit Favorites. Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.

  7. Xanodyne Pharmaceuticals | LinkedIn

    Learn about working at Xanodyne Pharmaceuticals. Join LinkedIn today for free. See who you know at Xanodyne Pharmaceuticals, leverage your professional network, and get hired.

  8. Xanodyne Pharmaceuticals Inc: Company Profile - Bloomberg

    Company profile & key executives for Xanodyne Pharmaceuticals Inc (XANO:-) including description, corporate address, management team and contact info.

  9. Xanodyne Pharmaceuticals - Newport, KY -

    Xanodyne Pharmaceuticals: A speciality pharmaceutical company focused on products for women's health care and pain management.

  10. ROXICODONE (Oxycodone Hydrochloride Tablets USP) [Xanodyne ...

    [Xanodyne Pharmaceuticals, Inc.] 10004436/01 CII Rx only . DESCRIPTION . ROXICODONE® (oxycodone hydrochloride tablets USP) is an opioid analgesic.

  11. Ferring acquires LYSTEDA™ from Xanodyne Pharmaceuticals, Inc ...

    Global Acquisition Expands Ferring's Role in Women's Health Saint-Prex, Switzerland, 10 May 2010 - Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy ...